• 100% of the 42 studies to date report positive effects. Random effects meta-analysis for early treatment and pooled effects shows a reduction of 83%, RR 0.17 [0.11-0.28]. Prophylactic use shows a reduction of 89%, RR 0.11 [0.05-0.23]. Mortality results show 75% lower mortality, RR 0.25 [0.14-0.44] for all treatment delays, and 86% lower, RR 0.14 [0.03-0.62] for early treatment.• 100% of the 21 Randomized Controlled Trials (RCTs) report positive effects, with an estimated reduction of 70%, RR 0.30 [0.19-0.49].• The probability that an ineffective treatment generated results as positive as the 42 studies to date is estimated to be 1 in 4 trillion (p = 0.00000000000023).

Early treatment	83% improvement	RR 0.17 [0.11-0.28]
Late treatment	51% improvement	RR 0.49 [0.37-0.66]
Prophylaxis	89% improvement	RR 0.11 [0.05-0.23]

Total	42 studies	331 authors	14,906 patients
RCT	21 studies	180 authors	2,869 patients

Indication	Studies	Patients	Effect size	WHO status
Scabies [Kory]	6	613	0.65 [0.54‑0.78] 35% improvement	Approved
COVID-19 (RCT)	21	2,869	0.30 [0.19‑0.49] 70% improvement	Not approved yet
COVID-19 (all)	42	14,906	0.25 [0.19‑0.34] 75% improvement